Related Experiment Video

Updated: Jul 17, 2026

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Pyridoxal 5'-phosphate may be curative in early-onset epileptic encephalopathy

G F Hoffmann1, B Schmitt, M Windfuhr

  • 1Department of General Pediatrics, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.

Journal of Inherited Metabolic Disease
|January 12, 2007
PubMed

Insights

Pyridoxal 5'-phosphate (PLP) treatment is crucial for neonatal epileptic encephalopathy caused by pyridox(am)ine-5'-phosphate oxidase (PNPO) deficiency. Early PLP intervention can lead to normal development, while delayed treatment results in severe outcomes.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Neonatal epileptic encephalopathy (NEE) is a severe neurological disorder.
  • Inborn errors of metabolism are a significant cause of NEE.
  • Conventional antiepileptic drugs are often ineffective for metabolic NEE.

Purpose of the Study:

  • To investigate the efficacy of pyridoxal 5 -phosphate (PLP) in treating NEE caused by PNPO deficiency.
  • To highlight the importance of early diagnosis and intervention for PNPO deficiency.

Main Methods:

  • Case study of six children with PNPO deficiency presenting with NEE.
  • Analysis of clinical outcomes based on the timing of PLP treatment.
  • Biochemical analysis to identify atypical findings.

Main Results:

  • Two children treated early with PLP showed normal development or moderate psychomotor retardation.
  • Four children with late or no PLP treatment experienced mortality or severe intellectual disability.
  • All patients exhibited unique biochemical markers.

Conclusions:

  • Pyridoxal 5 -phosphate (PLP) is a potentially life-saving and development-preserving treatment for PNPO deficiency.
  • Early PLP administration is critical for improving outcomes in NEE due to PNPO deficiency.
  • Mandatory screening and prompt PLP treatment for suspected NEE cases are recommended.

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...